NCT05653492View on ClinicalTrials.gov

Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2025

Conditions
Pediatric Kidney Disease
Interventions
DRUG

Sulforaphane

Dosing study one to four 30 mg/d tablets depending on weight

Trial Locations (1)

14642

University of Rochester Medical Center, Rochester

All Listed Sponsors
collaborator

Renal Research Institute

OTHER

lead

University of Rochester

OTHER